Speakers: Anne-Marie Duliege, MD, Chief Medical Officer, Pancreatic Cancer Network (PanCAN)
Organizers:
Date: 2021-12-07
Time: 11:30-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-12-07  (it will close sooner if the seating cap is reached)

About the Topic

Drug development in metastatic pancreatic ductal adenocarcinoma (PDAC) has been disappointing with a 5 year survival rate of only 10% despite considerable effort.  Precision Promise is a transformative, adaptive registration clinical trial platform that attempts to correct this by continuously and rapidly evaluating novel therapeutic options while nurturing enhanced cooperation among groups representing patient advocacy, pharmaceuticals, translational/clinical academia, and the FDA. This patient-centric study represents a fundamental shift that can substantially accelerate drug development for PDAC . PanCAN is also leading translational research by facilitating genetic testing of patients with pancreatic cancer (“Know Your Tumor” program), and has recently launched an Early Detection Initiative (EDI) in patients with recent onset diabetes.

As Chief Medical Officer for the Pancreatic Cancer Action Network, Anne-Marie Duliege, MD, is responsible for the strategic direction and operational oversight for the organization’s clinical initiatives, including PanCAN’s Precision Promise℠ clinical trial.

From 2004 to 2013, Dr. Duliege was VP then CMO and Head of Research and Clinical Development at Affymax. Under her leadership, her team completed an extensive development program and obtained FDA approval of the company’s lead product for anemia in dialysis patients. Prior to that, Dr. Duliege worked at Chiron and Genentech on various programs including an HIV vaccine and treatment. Prior to her career in the biopharmaceutical industry, Dr. Duliege was an epidemiologist with the National Institute of Science and Medical Research in Paris.